We are live on ! Find out more

ACHN

Achillion Pharmaceuticals

ACHN

Delisted

ACHN was delisted on the 27th of January, 2020.

127 hedge funds and large institutions have $415M invested in Achillion Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 41 increasing their positions, 38 reducing their positions, and 36 closing their positions.

New

Increased

Maintained

Reduced

Closed

1,106% more call options, than puts

Call options by funds: $3.12M | Put options by funds: $259K

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

27% more capital invested

Capital invested by funds: $327M → $415M (+$88.7M)

8% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 38

15% less funds holding

Funds holding: 149 → 127 (-22)

53% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 36

Holders

127

Holders Change

-22

Holders Change %

-14.77%

% of All Funds

2.91%

Holding in Top 10

Holding in Top 10 Change

Holding in Top 10 Change %

+50%

% of All Funds

0.07%

New

Increased

Reduced

Closed

Calls

$3.12M

Puts

$259K

Net Calls

+$2.87M

Net Calls Change

+$2.5M

Top Buyers

Rank	Fund	Capital Flow
1	T. Rowe Price Associates Baltimore, Maryland	+$15.2M
2	AC Armistice Capital New York	+$14.1M
3	GPP Great Point Partners Greenwich, Connecticut	+$12.1M
4	Goldman Sachs New York	+$8.8M
5	Citadel Advisors Miami, Florida	+$7M

Top Sellers

Rank	Fund	Capital Flow
1	O OrbiMed New York	-$23.5M
2	Morgan Stanley New York	-$14.7M
3	SCM Sarissa Capital Management Greenwich, Connecticut	-$6.55M
4	BI BVF Inc San Francisco, California	-$4.63M
5	Renaissance Technologies New York	-$4.28M

#	Name	Holding	Trade Value	Shares Change	Change in Stake
26	PA 26 Perceptive Advisors New York	$3.71M	–	–	–
27	ACH 27 ArrowMark Colorado Holdings Denver, Colorado	$3.47M	–	–	–
28	28 Renaissance Technologies New York	$3.25M	-$4.28M	-1,306,568	-60%
29	DCM 29 DAFNA Capital Management Los Angeles, California	$3.22M	-$262K	-80,000	-8%
30	SDIC 30 South Dakota Investment Council Sioux Falls, South Dakota	$3.09M	–	–	–
31	TCIM 31 TIAA CREF Investment Management New York	$2.96M	+$1.42M	+432,818	+119%
32	AG 32 Artal Group Luxembourg	$2.78M	–	–	–
33	33 Charles Schwab San Francisco, California	$2.6M	+$496K	+151,659	+28%
34	RPAM 34 Rhenman & Partners Asset Management Stockholm, Sweden	$2.48M	–	–	–
35	CS 35 Candriam SCA Strassen, Luxembourg, Luxembourg	$2.41M	+$704K	+215,000	+49%
36	36 Bank of New York Mellon New York	$2.33M	+$127K	+38,850	+7%
37	TCM 37 Tekla Capital Management Boston, Massachusetts	$2.29M	–	–	–
38	SCM 38 Sarissa Capital Management Greenwich, Connecticut	$1.85M	-$6.55M	-2,000,000	-80%
39	QI 39 QS Investors New York	$1.67M	-$98.5K	-30,113	-6%
40	40 Stifel Financial St. Louis, Missouri	$1.49M	–	–	–
41	41 Bank of America Charlotte, North Carolina	$1.35M	-$257K	-78,595	-18%
42	PAM 42 Panagora Asset Management Boston, Massachusetts	$1.26M	-$386K	-117,995	-26%
43	43 D.E. Shaw & Co New York	$1.25M	-$96.3K	-29,411	-8%
44	44 Morgan Stanley New York	$1.21M	-$14.7M	-4,486,067	-93%
45	45 UBS Group Zurich, Switzerland	$1.13M	+$680K	+207,824	+214%
46	VEA 46 Virtus ETF Advisers New York	$973K	+$462K	+141,020	+116%
47	PP 47 PDT Partners New York	$825K	+$728K	+222,500	New
48	OAM 48 Oxford Asset Management Oxford, United Kingdom	$812K	-$470K	-143,633	-40%
49	49 California State Teachers Retirement System (CalSTRS) West Sacramento, California	$766K	+$72.1K	+22,017	+12%
50	50 TD Asset Management Toronto, Ontario, Canada	$754K	+$665K	+203,287	New

ACHN Hedge Fund Activity: Q1 2018 in Review

127 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q1 2018, worth a combined $415M — up 27% from $327M a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of ACHN and 17 opened new positions — a net loss of 19 holders — while 38 trimmed existing stakes and 41 added.

The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $15.2M. The largest seller was OrbiMed, exiting entirely with an estimated $23.5M sold.

127 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q1 2018, down from 149 in Q4 2017.
Funds reported $415M of Achillion Pharmaceuticals stock for Q1 2018, up 27% quarter-over-quarter.
17 funds opened new Achillion Pharmaceuticals positions in Q1 2018 and 36 closed out, a net change of -19 holders.
The largest Achillion Pharmaceuticals buyer in Q1 2018 was T. Rowe Price Associates, an estimated $15.2M added.
The largest Achillion Pharmaceuticals seller in Q1 2018 was OrbiMed, an estimated $23.5M sold.

Based on aggregated 13F filings for Q1 2018.

Achillion Pharmaceuticals ACHN